We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Pauline Farmer-Koppenol Fenwick & West LLP

Results 1 to 5 of 6
Most popular |Most recent


Unanimous Supreme Court decision in Ass'n for Mol. Pathology v. Myriad Genetics Inc.

USA - June 13 2013 Today, a unanimous Supreme Court decision in Ass'n for Mol. Pathology v. Myriad Genetics, Inc., held that Myriad's claims directed to "a naturally...

Michael J. Shuster, Lynn H. Pasahow, Carolyn Chang.


Life sciences alert: Supreme Court issues groundbreaking decision limiting the types of methods that are eligible for patenting

USA - March 20 2012 Today, the U.S. Supreme Court handed down a unanimous decision holding that method claims for applying a law of nature using merely conventional steps are not eligible for patent protection....

Michael J. Shuster, Robert R. Sachs, Stuart P. Meyer, David Austin, Daniel Brownstone.


A comparison of US and EU biosimilars regimes

European Union, USA - January 20 2012 Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different from the generic small molecule pharmaceutical industry....

Michael J. Shuster.


Classen v. Inc. v. Biogen Idec et al. the latest installment in the patent-eligibility arena

USA - October 6 2011 On August 31, 2011, the Federal Circuit issued its long-awaited decision in Classen Immunotherapies, Inc. v. Biogen Idec et al....

Michael J. Shuster.


Patenting personalized medicine inventions after Myriad

USA - August 29 2011 The Federal Circuit’s recent decision in Assoc. for Mol. Pathology v. USPTO (2010-1406) (informally referred to as the Myriad decision), provides some clarity to entrepreneurs and scientists working in the personalized medicine industry....

Michael J. Shuster.